SX-682

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

SX-682  纯度: 98.52%

SX-682 是口服有效的 CXCR1CXCR2 变构抑制剂。SX-682 可以阻断肿瘤髓系抑制细胞 (MDSCs) 募集并增强 T 细胞活化和抗肿瘤免疫。

SX-682

SX-682 Chemical Structure

CAS No. : 1648843-04-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥1540 In-stock
5 mg ¥1500 In-stock
10 mg ¥2700 In-stock
25 mg ¥5400 In-stock
50 mg ¥8700 In-stock
100 mg ¥13000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SX-682 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Immunology/Inflammation Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Small Molecule Immuno-Oncology Compound Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Endocrinology Compound Library
  • Orally Active Compound Library

生物活性

SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity[1].

IC50 & Target[1]

CXCR1

 

CXCR2

 

体内研究
(In Vivo)

SX-682 (50 mg/kg; orally; twice a day on a Monday through Friday) has Meager to moderate effects as single agents on CRPC progression was observed, yet combination with ICB produced strong efficacy[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6NTac-Tyrtm1Arte female mice[2]
Dosage: 50 mg/kg
Administration: Orally; twice a day on a Monday through Friday
Result: Has Meager to moderate effects on CRPC progression.

Clinical Trial

分子量

467.20

Formula

C19H14BF4N3O4S

CAS 号

1648843-04-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 250 mg/mL (535.10 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1404 mL 10.7021 mL 21.4041 mL
5 mM 0.4281 mL 2.1404 mL 4.2808 mL
10 mM 0.2140 mL 1.0702 mL 2.1404 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.45 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Sun L, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019 Apr 4;4(7).

    [2]. Lu X, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 30;543(7647):728-732. 

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

发表回复